2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10,11-dihydrobenzo[6,7]oxepino[3,2-b]pyridine-7-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10,11-dihydrobenzo[6,7]oxepino[3,2-b]pyridine-7-carboxylic acid
• 英文别名: US10183917, Example 3；3-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-5,6-dihydro-[1]benzoxepino[3,2-b]pyridine-9-carboxylic acid
• 化学式: C₂₇H₂₀Cl₂N₂O₅
• 分子量: 523.372
• InChiKey: ATRNVMWUTDSCIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  94.7
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-溴-6-甲氧基-2-吡啶羧醛 在 盐酸 、 potassium phosphate 、 copper(l) iodide 、 三甲基氯硅烷 、 N,N-二甲基甘氨酸 、 sodium acetate 、 sodium hydride 、 caesium carbonate 、 对甲苯磺酸 、 sodium iodide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 40.33h， 生成 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10,11-dihydrobenzo[6,7]oxepino[3,2-b]pyridine-7-carboxylic acid
  参考文献：
  名称：

  发现三环法尼醇 X 受体激动剂 HEC96719，一种治疗非酒精性脂肪性肝炎的临床候选药物

  摘要：

  非酒精性脂肪性肝病 (NAFLD) 正在成为全球慢性肝病最主要的负担。非酒精性脂肪性肝炎 (NASH) 是 NAFLD 的进行性形式，可发展为肝硬化和肝细胞癌。不幸的是，目前 NASH 治疗的选择非常有限。在 NASH 的多种途径中，法尼醇 X 受体 (FXR)，一种核胆汁酸受体，被公认为重要的有效靶点。在这里，我们报告了基于先前的高亲和力非甾体分子 GW4064 的新型三环 FXR 激动剂化合物 HEC96719 的合成和表征。HEC96719在体外和体内表现出优于 GW4064 和奥贝胆酸的优异效力FXR活化的测定。它还显示出更高的 FXR 选择性和更有利的组织分布，主要在肝脏和肠道中。关于药代动力学特性、疗效和安全性的临床前数据总体表明，HEC96719 是一种有前途的 NASH 治疗候选药物。

  DOI：

  10.1016/j.ejmech.2021.114089

文献信息

• Tricyclic compounds and uses thereof in medicine
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：US10183917B2

  公开（公告）日：2019-01-22

  The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

  本发明涉及能与FXR结合并作为FXR调节剂的新型三环化合物，或其立体异构体、几何异构体、同分异构体、N-氧化物、水合物、溶质、代谢物、药学上可接受的盐或原药，以及该化合物用于治疗由FXR介导的疾病和/或病症的用途。本发明进一步提供了一种含有本文公开的化合物的药物组合物，以及一种治疗由FXR介导的疾病和/或病症的方法，该方法包括施用该化合物或药物组合物。
• Nitrogen-containing tricyclic compounds and uses thereof in medicine
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US10562910B2

  公开（公告）日：2020-02-18

  A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

  本发明描述了一种作为 FXR 调节剂的含氮三环化合物，或其立体异构体、几何异构体、同分异构体、N-氧化物、水合物、溶解物、代谢物、药学上可接受的盐或原药，以及该化合物用于治疗由 FXR 介导的疾病和/或状况的用途。此外，还描述了含有本文公开的化合物的药物组合物，以及通过施用该化合物或其药物组合物治疗由 FXR 介导的疾病和/或病症的方法。
• TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：EP3256468B1

  公开（公告）日：2020-04-08
• NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20190169203A1

  公开（公告）日：2019-06-06

  A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.
• [EN] TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS TRYCICLIQUES ET UTILISATIONS DE CEUX-CI EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2016127924A1

  公开（公告）日：2016-08-18

  The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.